Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Spectral Medical Inc T.EDT

Alternate Symbol(s):  EDTXF

Spectral Medical Inc. is a Canada-based late-stage theragnostic company advancing therapeutic options for sepsis and septic shock. The Company develops and commercializes a treatment for septic shock utilizing its Endotoxin Activity Assay (EAA) diagnostic and the Toraymyxin therapeutic (PMX). PMX is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream and is guided by the Company’s EAA. PMX is approved for therapeutic use in Japan and Europe and has been used safely and effectively on more than 340,000 patients to date. It has pioneered the development of biochemical markers for the clinical syndrome known as septic shock. It is continuing its legacy business of manufacturing and selling certain proprietary reagents. It develops, produces and markets recombinant proteins, antibodies and calibrators. These materials are sold for use in research and development, as well as in products manufactured by other diagnostic companies.


TSX:EDT - Post by User

Post by mercedesmanon Mar 01, 2023 3:17pm
197 Views
Post# 35313283

EAA praise & the import of precision medicine and biomarkers

EAA praise & the import of precision medicine and biomarkersEndotoxin Activity Assay. An excellent technique to measure LPS in a short time (15–20 min) is the endotoxin activity assay (EAA): a rapid test for the detection of endotoxemia in whole blood. EAA is a quick and easy diagnostic test based on a monoclonal antibody that identifies endotoxin. With this method, LPS activity is measured based on the corresponding oxidative burst of primed neutrophils (complexes of an anti-endotoxin antibody and endotoxin) and is detected via the chemiluminescence method []. With this approach, reliable quantification of the amount of endotoxin in a patient’s whole blood can be easily obtained.

6. Conclusions

Despite the availability of updated guidelines with the aim of improving outcomes, overall sepsis mortality has increased in the past decade. Understanding underlying mechanisms would help to identify drivers and to prevent reactions to infection. Even if each technology and each approach for endotoxin detection for sepsis diagnosis has its own advantages and limitations, the method used for the identification and quantification of LPS could be selected according to the context and situation. Emerging data and ongoing research on new innovative methods are expected to offer new diagnostic options for LPS evaluation. With the help of these promising technologies, several efforts should be addressed for a more detailed model of sepsis pathways: biomarkers’ identification and their quantification represent the most helpful in a clinical context. Biomarkers allow the development of targeted strategies, as shown by the haemoadsorption of inflammatory molecules, with the aim of early recovery, early recognition of sepsis complications, and improvement in predicting outcomes. In conclusion, considering the wide spectrum of etiology, clinical manifestation, and individual response to infection and therapy, an integrated approach of new technologies and therapies seems to be the most effective strategy to improve outcomes. 

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9818564/

<< Previous
Bullboard Posts
Next >>